Evidence map›Paper›PMID 36747268›Full record

ArticleAddiction science & clinical practice2023

Implementation of an integrated infectious disease and substance use disorder team for injection drug use-associated infections: a qualitative study.

Belén Hervera, Grace Seo, Tyler S Bartholomew, Teresa A Chueng, Edward Suarez, David W Forrest, Salma Hernandez, Allan E Rodriguez, Hansel E Tookes, Susanne Doblecki-Lewis and 1 more

Open access · goldAbstract read
In one paragraph

Article in Addiction science & clinical practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
5.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Belén HerveraDivision of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14Th St, Suite 851, Miami, FL, 33136, USA.
Grace SeoDivision of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14Th St, Suite 851, Miami, FL, 33136, USA.
Tyler S BartholomewDepartment of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.
Teresa A ChuengDivision of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14Th St, Suite 851, Miami, FL, 33136, USA.
Edward SuarezDivision of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14Th St, Suite 851, Miami, FL, 33136, USA.
David W ForrestDivision of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14Th St, Suite 851, Miami, FL, 33136, USA.
Salma HernandezDivision of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14Th St, Suite 851, Miami, FL, 33136, USA.
Allan E RodriguezDivision of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14Th St, Suite 851, Miami, FL, 33136, USA.
Hansel E TookesDivision of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14Th St, Suite 851, Miami, FL, 33136, USA.
Susanne Doblecki-LewisDivision of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14Th St, Suite 851, Miami, FL, 33136, USA.
David P SerotaDivision of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14Th St, Suite 851, Miami, FL, 33136, USA. dserota@med.miami.edu.ORCID 0000-0001-8505-6617
University of Miami · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHospitalizations for severe injection drug use-related infections (SIRIs) are characterized by high costs, frequent patient-directed discharge, and high readmission rates. Beyond the health system impacts, these admissions can be traumatizing to people who inject drugs (PWID), who often receive inadequate treatment for their substance use disorders (SUD). The Jackson SIRI team was developed as an integrated infectious disease/SUD treatment intervention for patients hospitalized at a public safety-net hospital in Miami, Florida in 2020. We conducted a qualitative study to identify patient- and clinician-level perceived implementation barriers and facilitators to the SIRI team intervention.

methodsParticipants were patients with history of SIRIs (n = 7) and healthcare clinicians (n = 8) at one implementing hospital (Jackson Memorial Hospital). Semi-structured qualitative interviews were performed with a guide created using the Consolidated Framework for Implementation Research (CFIR). Interviews were transcribed, double coded, and categorized by study team members using CFIR constructs.

resultsImplementation barriers to the SIRI team intervention identified by participants included: (1) complexity of the SIRI team intervention; (2) lack of resources for PWID experiencing homelessness, financial insecurity, and uninsured status; (3) clinician-level stigma and lack of knowledge around addiction and medications for opioid use disorder (OUD); and (4) concerns about underinvestment in the intervention. Implementation facilitators of the intervention included: (1) a non-judgmental, harm reduction-oriented approach; (2) the team's advocacy for PWID as a means of institutional culture change; (3) provision of close post-hospital follow-up that is often inaccessible for PWID; (4) strong communication with patients and their hospital physicians; and (5) addressing diverse needs such as housing, insurance, and psychological wellbeing.

conclusionIntegration of infectious disease and SUD treatment is a promising approach to managing patients with SIRIs. Implementation success depends on institutional buy-in, holistic care beyond the medical domain, and an ethos rooted in harm reduction across multilevel (inner and outer) implementation contexts.

Indexed as

Communicable DiseasesOpioid-Related DisordersSubstance Abuse, IntravenousDelivery of Health CareHumansQualitative ResearchEndocarditisHarm reductionImplementation scienceInfectious diseasesInjection drug useOpioid use disorder

Identifiers

PMID36747268
PMCPMC9902242
OpenAlexW4319299126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.